An open-label, multi-center protocol for patients who have completed a previous Novartis sponsored Secukinumab study and are judged by the investigator to benefit from continued Secukinumab treatment

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-504417-67-00

Acronym

CAIN457A02001B

Enrollment

332

Registered

2023-08-21

Start date

2020-12-22

Completion date

Unknown

Last updated

2025-11-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ankylosing Spondylitis, Juvenile idiopathic Arthritis, Moderate to severe Chronic Plaque Psoriasis, Non-radiographic Axial Spondyloarthritis, Psoriatic Arthritis, Severe Chronic Plaque Psoriasis

Brief summary

Serious adverse events (SAEs), adverse events (AEs), and injection site reactions

Interventions

DRUGSECUKINUMAB

Eligibility

Sex/Gender

All

Age

0 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Serious adverse events (SAEs), adverse events (AEs), and injection site reactions	—

Countries

Belgium, Bulgaria, Czechia, Italy, Poland, Portugal, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026